When should data and safety monitoring committees share interim results in cardiovascular trials?

JAMA

Volumn 299, Issue 14, 2008, Pages 1710-1712

  Borer, Jeffrey S ^a   Gordon, David J ^b   Geller, Nancy L ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; DATA ANALYSIS; INFORMATION DISSEMINATION; NOTE; PRIORITY JOURNAL; SAFETY; TREATMENT PLANNING; ARTICLE; CARDIOLOGY; CLINICAL TRIAL; HUMAN; INTERDISCIPLINARY COMMUNICATION; PROFESSIONAL STANDARD; STANDARD; STATISTICAL ANALYSIS;

CARDIOLOGY; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA INTERPRETATION, STATISTICAL; HUMANS; INTERDISCIPLINARY COMMUNICATION;

EID: 41949085462     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.14.1710     Document Type: Note

References (10)

1. Sydes MR, Altman DG, Babiker AB, et al. Reported use of data monitoring committees in the main published reports of randomized controlled trials. Clin Trials. 2004;1(1):48-59.
2. Food and Drug Administration. Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees. http://www.fda.gov/cber/gdlns/clintrialdmc.htm. 2006. Accessed May 24, 2007.
3. DAMOCLES Study Group. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365(9460):711-722.
4. Ellenberg S, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials: A Practical Perspective. Chichester, England: Wiley; 2002.
5. Montori VM, Devereaux PJ, Adhikari NKJ, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294(17):2203-2209.
6. Pocock SJ. When (not) to stop a clinical trial for benefit. JAMA. 2005;294(17):2228-2230.
7. Proschan MA, Lan KKG, Wittes JT. Statistical Monitoring of Clinical Trials: A Unified Approach. New York, NY: Springer; 2006:131ff.
8. US Securities Exchange Commission. Final rule: selective disclosure and insider trading. 17 CFR parts 240, 243, and 249. http://www.sec.gov/rules/final/ 33-7881.htm. Accessed March 14, 2008.
9. Weekly NIH funding opportunities and notices: NIH guide for grants and contracts. NIH policy for data and safety monitoring, June 12, 1998. http://grants.nih.gov/grants/guide/notice-files/not98-084.html. Accessed March 14, 2008.
10. NIAID principles for use of a data and safety monitoring board (DSMB) for oversight of clinical trials, version 2.0. Bethesda, MD: NIAID; November 20, 2007: 1-8. http://www3.niaid.nih.gov/research/resources/toolkit/attachments/ DSMB_Policyv2.pdf. Accessed March 13, 2008.